Vitamin K is essential for blood coagulation and bone metabolism. Patients with severe disabilities are at increased risk of vitamin K deficiency because of antibiotic exposure, antiepileptic medications, and enteral feeding [1, 2]. We report two patients with severe disabilities who developed vitamin K deficiency‐related coagulopathy during antibiotic‐associated diarrhea while receiving enteral nutritional support.
1. Case 1
An 18‐year‐old female with trisomy 13 and Lennox–Gastaut syndrome, who was bedridden and receiving valproate, received gastrostomy feeding with ENORAS Liquid for Enteral Use (Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan) and RACOL‐NF Semi Solid for Enteral Use (Otsuka Pharmaceutical Factory, Tokushima, Japan). She developed fever and productive sputum. Chest CT showed bilateral infiltrates and she was hospitalized with bacterial pneumonia. Coagulation parameters were normal at admission: prothrombin time international normalized ratio (PT‐INR) of 1.04 and activated partial thromboplastin time (APTT) of 30.9 s. Piperacillin/tazobactam was started on hospital Day 1. By Day 5, she developed watery diarrhea (two to three times/day) and seizure clusters. Intravenous midazolam controlled the seizures but led to reduced peristalsis and abdominal distension. Enteral nutrition was discontinued on Day 14, followed by 5 days of fasting. After midazolam tapering, feeding was resumed with ELENTAL (Ajinomoto Co. Inc., Tokyo, Japan), an elemental diet selected to reduce the digestive burden because of abdominal distension and concern for gastrointestinal intolerance after fasting. On Day 24, coagulation tests were performed to assess possible valproate‐related adverse effects and showed a PT‐INR of 3.01 and APTT of 50.6 s. Protein induced by vitamin K absence or antagonist‐II (PIVKA‐II) was markedly elevated (17,789 mAU/mL), consistent with vitamin K deficiency‐related coagulopathy. Intravenous menatetrenone (20 mg) was administered. By day 25, PT‐INR and APTT normalized to 1.05 and 36.3 s, respectively. No bleeding symptoms were observed.
2. Case 2
A 26‐year‐old male with monocarboxylate transporter 8 deficiency, bronchial asthma, and epilepsy, who was bedridden, received gastrostomy feeding with ENORAS and was on phenobarbital. He was admitted with cough, increased secretions, and asthma exacerbation. PT‐INR and APTT on admission were 1.00 and 23.2 s, respectively. Methylprednisolone and isoproterenol were started. Cefotaxime was added because of persistent fever and pulmonary infiltrates. On Day 3, his respiratory status deteriorated, requiring intubation. He also developed watery diarrhea (two to three times/day). Stool tests confirmed Clostridium difficile toxin A/B and C. difficile overgrowth, leading to pseudomembranous colitis. Enteral nutrition was halted for 7 days, then resumed with ELENTAL as an easily digestible elemental diet because of diarrhea and concern for gastrointestinal intolerance after fasting. On Day 10, coagulation tests were performed because of fever and suspected disseminated intravascular coagulation, showing a PT‐INR of 6.20 and an APTT of 61.3 s. PIVKA‐II was markedly elevated (58,452 mAU/mL), consistent with vitamin K deficiency‐related coagulopathy. After intravenous menatetrenone (20 mg), PT‐INR and APTT improved to 1.34 and 30.5 s, respectively, by Day 11. No bleeding symptoms were observed. The clinical courses of both cases are shown in Figure 1.
FIGURE 1.

Two cases of clinical course are shown. Case 1: ABPC/SBT, ampicillin sodium/sulbactam sodium; APTT, activated partial thromboplastin time; LZD, linezolid; PIPC/TAZ, tazobactam piperacillin hydrate; PIVKA‐II, protein induced by vitamin K absence or antagonist‐II; PT‐INR, prothrombin time international normalized ratio. Case 2: CTX, cefotaxime sodium; CZOP, cefozopran hydrochloride; p.o., per os; VCM, vancomycin hydrochloride.
Vitamin K is primarily obtained from the diet and synthesized by intestinal flora. It is absorbed in the small intestine with bile and undergoes conversion between oxidized, reduced, and epoxide forms through the vitamin K cycle [2, 3]. Vitamin K deficiency may result from poor intake, microbiota disruption, or medications, especially in patients with severe disabilities receiving frequent antibiotics [1, 4].
According to the American Society for Parenteral and Enteral Nutrition, the recommended daily intake of vitamin K is 2–2.5 μg for infants, 60–75 μg for children, and 90–120 μg for adults [5]. After fasting, both patients resumed feeding with ELENTAL, which contains only 3 μg of vitamin K per 100 kcal. The estimated daily intake was 22% of the recommended level in Case 1 and 4% in Case 2. In both cases, vitamin K supplementation was not initiated at the time of formula change because coagulation abnormalities had not yet been recognized. Antibiotic therapy may have reduced intestinal vitamin K‐producing bacteria, and the combination of fasting, diarrhea, and low vitamin K content in the enteral formula likely contributed to the deficiency. Vitamin K status and intake should therefore be carefully assessed, particularly after fasting, diarrhea, or antibiotic exposure, and supplementation or coagulation monitoring should be considered when formulas with low vitamin K content are used.
Author Contributions
Y.M. wrote the manuscript. R.F., Y.M., and H.S. provided patient care. Y.I. reviewed and provided advice regarding the manuscript. All the authors have read and approved the final version of the manuscript.
Consent
Written informed consent for publication was obtained from the patients or their legal guardians.
Conflicts of Interest
The authors declare no conflicts of interest.
Acknowledgments
The authors thank the patients and the parents for their cooperation.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
References
- 1. Yoshikawa H., Yamazaki S., Watanabe T., and Abe T., “Vitamin K Deficiency in Severely Disabled Children,” Journal of Child Neurology 18 (2003): 93–97. [DOI] [PubMed] [Google Scholar]
- 2. Shearer M. J., “Vitamin K,” Lancet 345 (1995): 229–234. [DOI] [PubMed] [Google Scholar]
- 3. Paulus M. C., Drent M., Kouw I. W. K., Balvers M. G. J., Bast A., and van Zanten A. R. H., “Vitamin K: A Potential Missing Link in Critical Illness–A Scoping Review,” Critical Care 28 (2024): 212. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Yokoyama S., Kawai M., Goto K., Watanabe N., Uehara M., and Sugiyama K., “Coagulopathy by Vitamin K Deficiency: Clinical Pitfall in a Case With Cerebral Palsy Under Long‐Term Tube Feeding,” Brain & Development 31 (2009): 449–451.18774664 [Google Scholar]
- 5. Vanek V. W., Borum P., Buchman A., et al., “A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi‐Trace Element Products,” Nutrition in Clinical Practice 27 (2012): 440–491. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
